#United States #Los Angeles #DJS Law Group #Hims & Hers #Hims

DJS Law Group Initiates Investigation into Hims & Hers Health, Inc.

On July 31, 2025, DJS Law Group announced the commencement of an investigation concerning Hims & Hers Health, Inc., a company listed on the NYSE under the ticker symbol HIMS. This inquiry is focused on possible violations of securities laws, specifically regarding allegations that the company may have disseminated misleading information to investors or failed to disclose critical details affecting stock performance.

One significant aspect of this investigation follows the press release issued by Novo Nordisk on June 23, 2025. In this release, Novo Nordisk announced the termination of its collaboration with Hims & Hers Health, Inc., citing a range of serious concerns, including illegal mass compounding and deceptive marketing practices attributed to the company. The statement revealed that the FDA had resolved the Wegovy® shortage, indicating that Novo Nordisk was sufficiently meeting demand nationwide. With this backdrop, Novo Nordisk had been working with telehealth companies to facilitate the transition of patients from substandard compounded drugs to genuine, FDA-approved Wegovy® through their NovoCare® Pharmacy. However, as emphasized in the press release, Hims & Hers had allegedly not complied with legal restrictions on the mass sale of compounded drugs, which purportedly jeopardized patient safety and wellbeing. Following this revelation, Hims & Hers shares plummeted by over 31.7% in afternoon trading, signaling a loss of investor confidence.

What This Means for Investors

If you are a shareholder of Hims & Hers Health, Inc. and have suffered a financial loss as a result of these developments, the DJS Law Group invites you to reach out for further assistance. Their expertise centers on advocating for investor rights through comprehensive legal support, focusing on securities class actions and corporate governance litigation. Their commitment remains towards enhancing investor returns by providing proactive counsel and rigorous advocacy.

The implications of these revelations bring additional scrutiny towards Hims & Hers and underline the importance of transparency and ethical practices in the healthcare sector. As regulatory bodies and legal experts delve into the nuances of the company's operations, affected investors are urged to stay informed and consider their options for legal recourse.

DJS Law Group's Commitment to Investors

DJS Law Group prides itself on working with a global roster of sophisticated hedge funds and alternative asset managers, ensuring that their clients’ litigation claims are treated as valuable assets demanding respect. The firm has established a strong reputation in pursuing justice for aggrieved shareholders through aggressive legal representation.

In summary, the investigation into Hims & Hers Health, Inc. serves as a crucial reminder of the responsibilities companies hold regarding accurate communications with their investors. As developments unfold, affected stakeholders are encouraged to report their experiences and engage with DJS Law Group to understand their potential claims and legal options.

For any further inquiries or to discuss your situation in detail, contact David J. Schwartz at the DJS Law Group via the details provided in the press release. Safeguarding your rights as an investor is paramount during these turbulent times.